INSM Q3 2025

Q1 2026 Q3 2025 Q2 2025 Q1 2025

Earnings

Insmed delivered a strikingly mixed Q3 2025, with revenue soaring 52.4% year over year to $142.34 million, well ahead of the $115.49 million consensus, while its per-share loss of $1.75 missed the $-1.37 estimate by 28.02% as the company absorbed the… Read more Insmed delivered a strikingly mixed Q3 2025, with revenue soaring 52.4% year over year to $142.34 million, well ahead of the $115.49 million consensus, while its per-share loss of $1.75 missed the $-1.37 estimate by 28.02% as the company absorbed the heavy costs of launching its newly approved BRINSUPRI. The FDA-approved DPP1 inhibitor, the first treatment authorized for non-cystic fibrosis bronchiectasis, generated $28.10 million in net sales during its partial debut quarter, drawing roughly 2,550 patients and prescriptions from approximately 1,700 physicians, though management noted that inventory stocking accounted for about 40% of those sales and is unlikely to repeat at that level in Q4. ARIKAYCE, meanwhile, posted $114.30 million in quarterly revenue, up 22% year over year, prompting Insmed to raise its full-year ARIKAYCE guidance to $420 million–$430 million. Total operating expenses climbed to $508.35 million, driven by a $104.65 million fair-value charge and near-doubling SG&A costs, widening the net loss to $370.02 million. With a positive EMA recommendation already secured and regulatory submissions accepted in the UK and Japan, international BRINSUPRI launches in 2026 represent the next major commercial catalyst for the company.